Web Site : http://www.chinamedicalsystem.com/

The Group was established in May 1995, and is a fully integrated, profitable pharmaceutical group focusing on research development, manufacturing and sales & marketing of pharmaceuticals. On 28 December 2006, China Medical System Holdings Limited was incorporated, becoming the current holding company of the Group. With 12 years of history in China, a strong own professional sales & marketing and R&D team was built. Currently, CMS has 5 products with sole distribution rights in the PRC, 3 in-house developed products and a range of medical equipment in marketing and 8 new drugs under development, ranging from pending Chinese drug authority's final approval, clinical test stages & early stage of R&D. CMS is one of the two foreign companies which have obtained China national drug distribution network license.

RNS Number : 3098A
China Medical Systems Holdings Ltd
31 July 2008


China Medical System has been approved to commence the Phase 2 clinical trial for a novel cancer treatment

China Medical System Holdings Ltd. (AIM: CMSH), the integrated and profitable Chinese pharmaceutical company is pleased to announce that it has received approval from the Chinese State Food and Drug Administration (SFDA) to commence the Phase II clinical trial for CMS024-02 (Tyroservatide), an in-house developed novel drug for the treatment of non-small cell lung cancer, one of the most common malignant tumours in China.

This marks a positive development for CMS024-02 following the submission of Phase II clinical trial application to SFDA in March 2007. The results of the Phase I clinical trial have demonstrated that CMS024-02 is safe and well tolerated by patients. The Company plans to initiate the Phase II Clinical Trial Protocol in the second half of 2008.

Mr Lam Kong, Chairman of China Medical System Holdings Ltd., said: 'We are very pleased with the approval of CMS024-02 for further clinical trial from SFDA. It is the second novel drug we have developed in house to Phase II trial. While our sales and marketing business is still growing, we are pleased that we have also made great progress in our R&D pipeline.'